115 related articles for article (PubMed ID: 7581115)
21. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
[TBL] [Abstract][Full Text] [Related]
23. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
[TBL] [Abstract][Full Text] [Related]
25. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
26. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
[TBL] [Abstract][Full Text] [Related]
27. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
28. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
[TBL] [Abstract][Full Text] [Related]
31. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
[TBL] [Abstract][Full Text] [Related]
32. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
33. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
Phillips GL; Nevill TJ; Spinelli JJ; Nantel SH; Klingemann HG; Barnett MJ; Shepherd JD; Chan KW; Meharchand JM; Sutherland HJ
Bone Marrow Transplant; 1995 Feb; 15(2):213-9. PubMed ID: 7539667
[TBL] [Abstract][Full Text] [Related]
34. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Bertz H; Potthoff K; Mertelsmann R; Finke J
Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
[TBL] [Abstract][Full Text] [Related]
35. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
[TBL] [Abstract][Full Text] [Related]
36. [Feasibility of early tapering and discontinuation of cyclosporine to intensify the graft-versus-leukemia effect in patients with advanced hematologic neoplasms].
Fujimaki K; Fujisawa S; Aotsuka N; Saito K; Kanamori H; Matsuzaki M; Takahashi S; Okamoto S; Sakamaki H; Maruta A
Rinsho Ketsueki; 2001 Sep; 42(9):680-4. PubMed ID: 11680978
[TBL] [Abstract][Full Text] [Related]
37. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
38. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
Hernández-Boluda JC; Marín P; Carreras E; Aguilar JL; Grañena A; Rozman C; Montserrat E
Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]